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Translational Relevance
EphA2 is considered an important therapeutic target as it is involved in many processes crucial to malignant progression. Among the various therapeutic strategies targeting EphA2, dasatinib is the farthest along with regard to clinical development. However, reliable predictors of response and the mechanisms relevant to dasatinib response have been largely lacking. We have identified a set of molecular predictors of dasatinib sensitivity in uterine cancer that may have significant implications for ongoing dasatinib-based clinical trials. Our key findings are that CAV-1, EphA2 phosphorylation at S897 and the status of PTEN are key determinants of dasatinib response. Moreover, we have identified a previously unknown mechanism involving the association between CAV-1, EphA2 and the heterodimer BRAF/CRAF, which has implications for designing new therapeutic combinations.
Introduction
EphA2 is a receptor tyrosine kinase involved in many processes crucial to malignant progression (1-3).
Overexpression of EphA2, which has been reported for many human cancers, including breast, melanoma, prostate, lung, ovarian (4, 5) and uterine cancers (6, 7) , is often associated with poor prognostic features (8) . For these reasons, EphA2 is considered an important therapeutic target.
Various therapeutic strategies targeting EphA2 have been developed, including monoclonal antibodies, immunoconjugates, small-molecule tyrosine kinase inhibitors, vaccines, and RNA interference (9, 10) .
Among these, dasatinib is the farthest along with regard to clinical development, even though it was primarily developed as an oral dual inhibitor of Bcr/Abl and Src family kinases. Genomic and proteomic profiling have shown EphA2 to be a direct target of dasatinib (11) (12) (13) . Dasatinib has shown activity in a fraction of patients with solid tumors (14) (15) (16) (17) ; however, reliable predictors of response to this agent are not known.
Here, we sought to identify a set of markers in uterine carcinoma that are essential for dasatinib response and to investigate the underlying mechanisms of response based on EphA2 function. We discovered that caveolin-1 (CAV-1)-mediated cross-talk between EphA2 and BRaf is a key determinant of dasatinib response in uterine cancer cells. Moreover, EphA2 phosphorylation at S897 and the status of PTEN are required for response to dasatinib. 
Materials and Methods

Cell Cultures
We selected uterine cancer cell lines HEC1-A, Ishikawa, SKUT-2, RL95-2 and KLE (all EphA2 positive) and SPEC-2, AN3CA and HEC-265 (all EphA2 negative). Cells were purchased from the MD Anderson Characterized Cell Line Core Facility (Houston, Texas), which supplies authenticated cell lines. The cell lines were routinely tested to confirm the absence of mycoplasma, and all experiments were performed with cell lines at 60%-80% confluence. Cells were maintained in specific culture medium as described previously (6) . The molecular features of cell lines (EphA2 status, CAV-1 status, RAS mutation, and PTEN mutation) are listed in Fig 1a (left) .
MTT Assay
Inhibition of cell growth by dasatinib was detected using the MTT cell proliferation assay, a tetrazoliumbased colorimetric assay performed in quadruplicate. Additional details regarding the treatment and MTT assay are provided in the Supplementary Methods (available online).
Western Blot Analysis and IP Analyses of Dasatinib Targets In Vitro
The expression levels of pEphA2 
Double Immunofluorescence Staining
To test the dynamic changes in the localization of EphA2, CAV-1, and BRaf in SKUT-2 cells treated with dasatinib at 100 nM for 16 hours, double staining was carried out using the rabbit monoclonal antibody against CAV-1 (red) and mouse monoclonal antibody for BRaf (green) or EphA2 (red or green). The stained cells were visualized by confocal microscopy at x200 magnification.
In Situ Proximity Ligation Assay
In situ PLA was performed according to manufacturer's instructions (Olink Bioscience). Briefly, after incubation with primary antibodies, the cells were incubated with a combination of corresponding PLA probes, secondary antibodies conjugated to oligonucleotides (mouse MINUS and rabbit PLUS).
Subsequently, ligase was added forming circular DNA strands when PLA probes were bound in close proximity, along with polymerase and oligonucleotides to allow rolling circle amplification. Fluoroscently labeled probes complementary in sequence to the rolling circle amplification product was hybridized to the rolling circle amplification product (Duolink Detection Kit 563; Olink Bioscience). Thus, each individual pair of proteins generated a spot (blob) that could be visualized using fluorescent microscopy at x200 magnification.
Transfection of siRNA
Research. SiRNA was purchased from Sigma-Aldrich (Woodlands, TX). A non-silencing siRNA that did not share sequence homology with any known human mRNA based on a BLAST search was used as control for target siRNA. For in vitro delivery, siRNA (5 ȝg) was incubated with 30 ȝL RNAiFect transfection reagent (Qiagen) for 10 minutes at room temperature and added to cells in culture at 80% confluence in 35 mm culture plates. The medium was changed 6 hours later, and cells collected after 48 hours as lysate for Western blot analysis. 
Detection of Multiple
Orthotopic In Vivo Model of Uterine Cancer and Tissue Processing
All animal studies were approved and supervised by the MD Anderson Institutional Animal Care and Use Committee. Two uterine cancer cell lines, SPEC-2 (no EphA2 expression) and SKUT-2 (high EphA2 expression) were used for in vivo experiments as previously described (6) . For in vivo therapy experiments, 10 mice were randomly allocated into four treatment groups: control, dasatinib (15 mg/kg oral, daily), paclitaxel (100 ȝg in 200 ȝL of PBS intraperitoneally, weekly), or dasatinib plus paclitaxel.
Therapy was initiated 2 weeks after cell injection. Additional details are provided in the Supplementary Methods (available online).
Immunohistochemical Staining in the Mouse Uterine Tumor Samples
Paraffin-embedded tissues were used to detect cell proliferation (with Ki67) and apoptosis (with cleaved caspase 3). The sections were incubated with the Ki67 antibody (1:400; Dako) and monoclonal mouse antibody against cleaved caspase 3 (1:100; Biocare Medical, Concord, CA). CD31 staining with rat monoclonal anti-mouse CD31 (1:800, PharMingen, San Diego, CA) was performed on frozen sections.
Additional details regarding IHC method are provided in the Supplementary Methods (available online). 
Statistical Analysis
For in vivo therapy experiments, 10 mice were used in each group, which provided the power to detect a 50% reduction in tumor size (ȕ error = 0.2). Continuous variables were compared using Student's t test (two groups) or analysis of variance (all groups) if the data were normally distributed. For nonparametric distributions, the Mann-Whitney U or Kruskal-Wallis test (all groups) was used. A value of p<0.05 with two-tailed testing was deemed statistically significant.
Research. 
Results
In Vitro Effect of Dasatinib on EphA2-Positive or -Negative Uterine Cancer Cell Lines
We first assessed the effect of dasatinib on a panel of six uterine cancer cell lines with known EphA2 expression levels (Fig 1a, left) . The median inhibitory concentration (IC 50 ) of these cell lines ranged from 0.03 to 17.9 μM (Fig 1a, middle) . Among these, EphA2-positive SKUT-2 cells were the most sensitive to dasatinib, whereas EphA2-negative SPEC-2 cells were the most resistant (Fig 1a, right) , suggesting that EphA2 status is a potential determinant of dasatinib sensitivity. The exception to this pattern was the EphA2-positive HEC1-A cell line (harbors a RAS mutation), with a higher IC 50 value than other EphA2-negative cells. These observations were further supported by EphA2-negative HEC-265 and EphA2-positive KLE uterine cancer cells, and by ectopic expression of EphA2 in the EphA2-negative A2780 ovarian cancer cells (Supplementary Figs S1a and S1b).
Wild-Type PTEN Increased Sensitivity to Dasatinib in EphA2 Positive Cell Lines In Vitro
We found that dasatinib exhibited less growth inhibition in EphA2 positive RL95-2 cells, which harbors high basal level of p-AKT
S473
. Therefore, next we addressed whether PTEN, which is frequently altered in uterine carcinoma (19), influences response to dasatinib through its effects on p-AKT S473 . AKT activation and PTEN mutation status in a panel of uterine cancer cell lines is shown in Figs 1a and 1b.
Next, we transfected wild-type or mutant PTEN into ishikawa cells carrying mutant PTEN. The dasatinib-sensitivity of ishikawa cells transfected with wild type PTEN was significantly enhanced by 5- fold, compared to that with parental cells carrying PTEN mutation ( Supplementary Fig S2) , suggesting that wild type PTEN is also a determinant of dasatinib sensitivity in uterine cancer cells.
In Vitro Effects of Dasatinib on Src/FAK/EphA2 Signaling Pathway
Next, we examined signaling events in the Src/FAK/EphA2 pathway known to be perturbed by dasatinib. The expression level of the traditional targets of dasatinib, including pAKT (Fig 1b) . These results support the known effects of dasatinib, but they do not explain the sensitivity of specific uterine cancer cell lines to it.
pEphA2 S897 Status is an Important Determinant of Response to dasatinib in Uterine Cancer Cells
Given the differential expression of EphA2 in dasatinib-sensitive versus -resistant cell lines and the role of ligand-independent pEphA2 S897 in many oncogenic functions (20), we next examined the effects of dasatinib on pEphA2
S897
. The expression of pEphA2 S897 was significantly decreased in SKUT-2 cells , but moderately so in HEC1-A and Ishikawa cells (Fig 1b and Suplementary Fig S4) . Furthermore, because the expression levels of pEphA2 S897 and pEphA2 Y594 are inversely related (20) , EphA2 tyrosine phosphorylation was decreased in HEC1-A and Ishikawa cells, but increased in SKUT-2 cells, after dasatinib treatment (Fig 1c) . . The cells with constitutively activated pEphA2 S897 had reduced sensitivity to dasatinib, whereas the cells with inactivated pEphA2 S897 remained highly sensitive to dasatinib (Fig 1d) . These results confirmed that pEphA2 S897 status is an important determinant of response to dasatinib in uterine cancer cells (Table S1 ).
Identification of Predictive Molecular Markers
To explore other potential markers of response to dasatinib, we used RPPA to quantify protein expression of genes involved in cell cycle, apoptosis, angiogenesis, and adhesion that are modulated by dasatinib in the SPEC-2, SKUT-2, HEC1-A, and Ishikawa cell lines (Fig 2, Supplementary Figs (Figs 3a and 3b) .
Next, we carried out immunoprecipitation (IP) studies with antibodies against EphA2, CAV-1, and BRaf.
IP analysis showed direct binding between EphA2 and CAV-1, EphA2 and BRaf, and CAV-1 and BRaf in SKUT-2 cells treated with dasatinib (Fig 3c) , but not in HEC1-A and Ishikawa cells (data not shown), or in the absence of dasatinib. Meanwhile, our IP analysis showed that dasatinib induced the heterodimer of BRaf/CRaf in Ishikawa cells, but not in SKUT-2 cells (Fig 3d) , (Fig 3d) , likely due to the fact that HEC1-A bears a RAS mutation and is more resistant to dasatinib treatment (21) . To further explore the association between EphA2, CAV-1, and
BRaf, we immunostained SKUT-2 cells for these proteins with or without dasatinib treatment.
Immunofluorescence staining analysis showed that BRaf was translocated from the cytoplasm to the plasma membrane and co-localized with CAV-1 after dasatinib treatment (Figs 4a, left, and 4b, left).
EphA2 was also translocated and co-localized with CAV-1 after dasatinib treatment (Fig 4a, right, top) , and EphA2 and BRaf showed co-localization as well (Fig 4a, right, bottom) . No co-localization between BRaf and CAV-1 was observed following dasatinib treatment in SPEC-2 cells (Fig 4b, right) or in HEC1-
A and Ishikawa cells (data not shown). Furthermore, following CAV-1 gene silencing, the growthinhibitory effects of dasatinib on SKUT-2 cells were attenuated (Fig 4c) . There was no co-localization between BRaf and CAV-1 (Fig 4b, right) or between BRaf and EphA2 (data not shown) in SKUT-2 cells following CAV-1 silencing, indicating that a high level of CAV-1 is important for the response to dasatinib in tumor cells and required for recruiting BRaf in response to dasatinib therapy. EphA2 silencing resulted in partially increased sensitivity to dasatinib in SKUT-2 cells, but it did not alter the response to dasatinib in HEC1-A cells ( Supplementary Fig S5) , which suggests that EphA2 is also important for the response to dasatinib in tumor cells.
Research. To further investigate whether BRaf or EphA2 have the capability to interact with CAV-1 we used in situ proximity ligation assay (PLA), which is a unique method developed to visualize subcellular localization and protein-protein interactions in situ (22) . SKUT-2 and HEC1-A treated with or without dasatinib for 8 hours were incubated overnight with primary antibody pair of different species directed to BRaf or EphA2 (mouse monoclonal anibody) and to CAV-1 (rabbit monoclonal antibody), respectively. The secondary antibodies were modified by addition of complementary oligonucleotides capable of interacting when in close proximity, an event that was detected by PCR amplification using a fluorochrome-based detection method. We observed that the colocalization of CAV-1 with BRaf (Fig 4d, top) and EphA2 (Fig 4d, bottom) was increased substantially in SKUT-2 cells after dasatinib treatment, and that the majority of binding interactions were localized on the plasma membrane. No significant increase in the co-localization of CAV-1 with BRaf and EphA2 was observed following dasatinib treatment in HEC1-A cells. Notably, CAV-1 gene silencing by siRNA significantly inhibited the colocalization of CAV-1 with BRaf and EphA2 (Fig 4d) , indicating that high expression of CAV-1 in the cells is required for CAV-1 binding to BRaf or EphA2.
In Vivo Effects of Dasatinib in Orthotopic Models of Uterine Cancers
Next, we tested the effects of dasatinib-based therapy in orthotopic mouse models of EphA2-positive and -negative uterine carcinoma. In the EphA2-positive SKUT-2 model, dasatinib treatment resulted in To examine the biological effects of dasatinib-based therapy, we examined tumors from the SKUT-2 and SPEC-2 models for markers of tumor cell proliferation (Ki67), angiogenesis (CD31), and apoptosis (cleaved caspase 3). Changes in these markers mirrored the anti-tumor activity in response to dasatinib. Specifically, significant reductions in proliferation and microvessel density and increased apoptosis were noted in the SKUT-2 model (Fig 5c) , whereas more modest changes were noted with the SPEC-2 model (Fig 5d) . In addition, the expression level of pEphA2 S897 was significantly decreased in the SKUT-2 model(79% [p<0.01]) (Fig 5c, bottom) .
Expression of Predictive Markers in Human Samples
We next examined the expression of the putative dasatinib response markers (CAV-1, pEphA2 (Table S2) . pEphA2 S897 was overexpressed in none of the normal samples but 70% of tumors, whereas high pEphA2 Y594 expression was detected in 90% of normal samples and 10% of tumor samples.
Discussion
The focus of this work is on the multi-targeted tyrosine kinase dasatinib, which is used in the clinic for several diseases. Unfortunately, predictive markers guiding its use and subsequent response are largely absent resulting in "hit or miss" clinical application. Herein, we present evidence from in vitro and in vivo experiments for a set of markers essential for dasatinib response. Among these, CAV-1, EphA2 phosphorylation at S897 and the status of PTEN were key determinants of dasatinib response.
In addition, CAV-1-mediated cross-talk between EphA2 and BRaf is required for response to dasatinib whereby dasatinib drives BRaf and EphA2 to CAV-1 at the plasma membrane, disrupting the BRaf/CRaf heterodimer and thus down-modulation of the mitogen-activated protein kinase (MAPK) pathway in dasatinib-sensitive cells, but not in dasatinib-resistant cells (Fig 6b) .
The biological functions of CAV-1 on cancer cells have been controversial. CAV-1 is known to directly interact via its scaffolding domain with multiple signaling proteins and function as pre-organized signalosomes by sequestering and regulating proteins localized in caveolae, including receptor tyrosine kinases and their signaling effectors (23) . In general, caveolins bind to and inactivate signaling molecules (24) , including those of the MAPK signaling pathway (e.g., Ras, RAF-1, and MAPK) (25) .
Loss of CAV-1 expression confers a significant growth advantage that is associated with constitutive hyperactivation of the p42/44 MAPK pathway (26) . In addition, interaction between Eph families, including EphA2 and CAV-1, has been reported (27). It has been reported that the Eph feedback loop in the activation of the HRAS/RAF/ERK pathway also increases EphA2 expression (28). We found that dasatinib inhibited EphA2 signalling, but unexpectedly stimulated Braf recruitment to the cell membrane, potentially promoting changes in the phosphorylation status and triggering its kinase activity 
